Nanobiotix S.A [NBTX] vs Recursion [RXRX] Detailed Stock Comparison

Nanobiotix S.A. - ADR

NASDAQ
Loading...

Recursion Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Nanobiotix S.A. - ADR wins in 10 metrics, Recursion Pharmaceuticals Inc. wins in 7 metrics, with 0 ties. Nanobiotix S.A. - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Nanobiotix S.A. - ADR Recursion Pharmaceuticals Inc. Better
P/E Ratio (TTM) -67.61 -2.44 Recursion Pharmaceuticals Inc.
Price-to-Book Ratio N/A 1.64 N/A
Debt-to-Equity Ratio -1.33 6.89 Recursion Pharmaceuticals Inc.
PEG Ratio 422.85 0.04 Recursion Pharmaceuticals Inc.
EV/EBITDA -146.15 -2.10 Recursion Pharmaceuticals Inc.
Profit Margin (TTM) -73.52% 4.45% Recursion Pharmaceuticals Inc.
Operating Margin (TTM) -196.42% -328.80% Nanobiotix S.A. - ADR
Return on Equity 28.36% -59.54% Nanobiotix S.A. - ADR
Return on Assets (TTM) -10.06% -27.72% Nanobiotix S.A. - ADR
Free Cash Flow (TTM) $-33.97M $-380.44M Nanobiotix S.A. - ADR
1-Year Return 565.54% -35.98% Nanobiotix S.A. - ADR
Price-to-Sales Ratio (TTM) 45.83 24.83 Recursion Pharmaceuticals Inc.
Enterprise Value $1.81B $1.19B Nanobiotix S.A. - ADR
EV/Revenue Ratio 47.03 15.88 Recursion Pharmaceuticals Inc.
Gross Profit Margin (TTM) N/A 59.62% N/A
Revenue per Share (TTM) $1 $0 Nanobiotix S.A. - ADR
Earnings per Share (Diluted) $-0.59 $-1.44 Nanobiotix S.A. - ADR
Beta (Stock Volatility) 0.55 1.01 Nanobiotix S.A. - ADR
Short % of Float 0.07% 34.94% Nanobiotix S.A. - ADR

Nanobiotix S.A. - ADR vs Recursion Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

NBTX
RXRX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Nanobiotix S.A. - ADR4.45%3.46%-27.92%9.18%66.16%67.74%
Recursion Pharmaceuticals Inc.4.44%-0.90%12.29%-2.95%-21.67%-21.67%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Nanobiotix S.A. - ADR565.54%580.84%144.77%109.31%109.31%109.31%
Recursion Pharmaceuticals Inc.-35.98%-64.69%-91.35%-89.94%-89.94%-89.94%

Performance & Financial Health Analysis: Nanobiotix S.A. - ADR vs Recursion Pharmaceuticals Inc.

MetricNBTXRXRX
Market Information
Market Cap i$1.63B$1.85B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i71,25811,402,630
90 Day Avg. Volume i70,52612,390,473
Last Close$37.12$3.29
52 Week Range$4.18 - $57.14$2.77 - $7.18
% from 52W High-35.04%-54.18%
All-Time High$57.00 (May 14, 2026)$42.81 (Jul 12, 2021)
% from All-Time High-34.88%-92.31%
Growth Metrics
Quarterly Revenue GrowthN/A6.82%
Quarterly Earnings GrowthN/A6.84%
Financial Health
Profit Margin (TTM) i-0.74%0.04%
Operating Margin (TTM) i-1.96%-3.29%
Return on Equity (TTM) i0.28%-0.60%
Debt to Equity (MRQ) i-1.336.89
Cash & Liquidity
Book Value per Share (MRQ)$-1.65$2.14
Cash per Share (MRQ)$1.09$1.41
Operating Cash Flow (TTM) i$-39,388,829$-371,808,000
Levered Free Cash Flow (TTM) i$-9,303,463$-208,521,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Nanobiotix S.A. - ADR vs Recursion Pharmaceuticals Inc.

MetricNBTX (Apr 24, 2026)RXRX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-67.61-2.44
Forward P/E i422.85-4.12
PEG Ratio i422.850.04
Price to Sales (TTM) i45.8324.83
Price to Book (MRQ) iN/A1.64
Market Capitalization
Market Capitalization i$1.63B$1.85B
Enterprise Value i$1.81B$1.19B
Enterprise Value Metrics
Enterprise to Revenue i47.0315.88
Enterprise to EBITDA i-146.15-2.10
Risk & Other Metrics
Beta i0.551.01
Book Value per Share (MRQ) i$-1.65$2.14

Financial Statements Comparison: Nanobiotix S.A. - ADR vs Recursion Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNBTX (2025)RXRX (2025)
Revenue/Sales i29.64M74.26M
Cost of Goods Sold iN/A70.95M
COGS % of Revenue i0.0%95.6%
Gross Profit iN/A3.30M
Gross Margin i0.0%4.4%
Research & Development i23.12M475.27M
Operating Income (EBIT) i-10.82M-648.13M
Operating Margin i-36.5%-872.8%
EBITDA i-8.83M-559.38M
EBITDA Margin i-29.8%-753.3%
Pre-Tax Income i-23.96M-644.90M
Pre-Tax Income % of Revenue i-80.8%-868.5%
Income Tax i3,000-136,000
Income Tax % of Revenue i0.0%-0.2%
Net Income (Profit) i-23.96M-644.76M
Profit Margin i-80.8%-868.3%

Balance Sheet & Liquidity Metrics

MetricNBTX (2025)RXRX (2025)
Cash & Equivalents i52.75M743.29M
Total Current Assets i62.75M812.85M
Total Current Assets % of Revenue i211.7%1,094.7%
Total Current Liabilities i57.51M147.71M
Total Current Liabilities % of Revenue i194.0%198.9%
Long-Term Debt i91.01M56.21M
Long-Term Debt % of Revenue i307.0%75.7%
Total Shareholders Equity i-84.48M1.13B
Retained Earnings i-23.96M-2.08B
Retained Earnings % of Revenue i-80.8%-2,795.7%
Property, Plant & Equipment i2.59M158.71M

Cash Flow Statement Comparison

MetricNBTX (2025)RXRX (2025)
Operating Cash Flow i-27.74M-422.39M
Operating Cash Flow % of Revenue i-93.6%-568.8%
Capital Expenditures i-538,000-6.47M
Free Cash Flow i-33.97M-380.44M
FCF Margin i-114.6%-512.3%
Debt Repayment i-4.74M-8.43M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNBTXRXRX
Shares Short i25,474174.40M
Short Ratio i0.3614.00
Short % of Float i0.07%34.94%
Shares Outstanding i48.39M528.18M
Float Shares i31.07M510.29M
% Held by Insiders i0.00%2.85%
% Held by Institutions i11.79%64.60%
% Held by Public i88.21%32.55%

Dividend Analysis & Yield Comparison: Nanobiotix S.A. - ADR vs Recursion Pharmaceuticals Inc.

MetricNBTXRXRX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A